HQL (abrdn Life Sciences Investors) Stock Analysis - Analyst Ratings

abrdn Life Sciences Investors (HQL) is a publicly traded Financial Services sector company. As of May 21, 2026, HQL trades at $17.22 with a market cap of $537.31M and a P/E ratio of 0.00. HQL moved +1.41% today. Year to date, HQL is +6.90%; over the trailing twelve months it is +38.84%. Its 52-week range spans $10.55 to $18.46. Rallies surfaces HQL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate HQL?

The average price target is $0.00.

HQL Key Metrics

Key financial metrics for HQL
MetricValue
Price$17.22
Market Cap$537.31M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.56%
52-Week High$18.46
52-Week Low$10.55
Volume202
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

HQL Analyst Consensus

HQL analyst coverage data. Average price target: $0.00.

Latest HQL News

Recent HQL Insider Trades

  • Pittard Christian bought 7.92K (~$133.75K) on Dec 16, 2025.
  • Saba Capital Management, L.P. sold 41.62K (~$588.55K) on Sep 22, 2025.
  • Saba Capital Management, L.P. sold 6.99K (~$98.54K) on Sep 19, 2025.

Common questions about HQL

What do analysts rate HQL?
The average price target is $0.00.
Does Rallies show HQL price targets?
Yes. Rallies tracks HQL analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is HQL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HQL. It does not provide personalized investment advice.
HQL

HQL